A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer

) of cisplatin was reduced by co‑treatment with FAP‑D, which could be attributable to the inhibition of cell migration by FAP‑D. Heterogeneous tumor growth was also strongly suppressed by cisplatin + FAP‑D. The apoptotic features of H1299/H460 cells and tumors were enhanced by cisplatin + FAP‑D treatment. In conclusion, the study demonstrated that FAP‑D can enhance the cisplatin sensitivity of H1299 cells and NSCLC tumors. The present findings shed new light into promising treatment strategies and demonstrated the potential clinical utility of cisplatin + FAP‑D for NSCLC treatment.